Seven Post Investment Office’s Vertex Pharmaceuticals VRTX Stock Holding History

Seven Post Investment Office’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-750	Closed	-$217K	–	56
2022 Q3	$217K	Hold	750	–	–	0.08%	42
2022 Q2	$211K	Buy	+750	New	+$201K	0.08%	45
2020 Q4	–	Sell	-750	Closed	-$204K	–	51
2020 Q3	$204K	Hold	750	–	–	0.08%	45
2020 Q2	$218K	Buy	+750	New	+$203K	0.09%	41

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Seven Post Investment Office's VRTX Position: Q4 2022 in Review

Seven Post Investment Office sold out of Vertex Pharmaceuticals (VRTX) in Q4 2022, closing a stake of 750 shares — an estimated $217K sold.

Seven Post Investment Office first reported a position in VRTX in Q2 2020 and held it in 4 quarters. The position peaked at $218K in Q2 2020. 1,223 funds tracked by Wall St. Rank hold VRTX as of Q4 2022.

Seven Post Investment Office reported no remaining Vertex Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Seven Post Investment Office sold 750 Vertex Pharmaceuticals shares in Q4 2022, an estimated $217K.
Seven Post Investment Office first reported a position in Vertex Pharmaceuticals in Q2 2020 and held it in 4 quarters.
Seven Post Investment Office's Vertex Pharmaceuticals position peaked at $218K in Q2 2020.
1,223 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2022.

Based on Seven Post Investment Office's 13F filing for Q4 2022, filed 31 Jan 2023.